Epitomics Inc., a biotechnology company commercializing the next generation of antibodies based on its ground breaking Rabbit Monoclonal Antibody (RabMAb) technology, announced that the company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) programme.

The goal of the project is to develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers, and then use the captured peptides to quantify the biomarkers by mass spec platforms such as SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) and iMALDI (immuno-Matrix-Assisted Laser Desorption/Ionization) assays.

Epitomics has successfully completed the first phase of the project to generate and affinity purify rabbit polyclonal antibodies against these biomarkers. The current project is the continuation into phase II which involves developing rabbit monoclonal antibodies against selected biomarkers that have been validated in phase I.

“We are excited to be working with the NCI and look forward to developing quality antibodies that will be key tools in their ongoing research activities,” said Guo-Liang Yu, PhD, CEO of Epitomics, Inc.

Epitomics Inc, is a biotechnology company dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The Company's core technology is its unique and proprietary RabMAb (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays.